Sputum and serum calprotectin are useful biomarkers during CF exacerbation

Gray, R.D.
Imrie, M.
Boyd, A.C.
Porteous, D.
Innes, J.A.
Greening, A.P.

Open link

Publication date

May 2010

DOI

10.1016/j.jcf.2010.01.005

Publisher

European Cystic Fibrosis Society. Published by Elsevier B.V.

Abstract

AbstractBackgroundAdequate monitoring of cystic fibrosis lung disease is difficult. CF exacerbation offers a unique setting to test the utility of biomarkers in the assessment of changing airways inflammation. We hypothesised that levels of calprotectin in sputum (and serum) would change informatively following treatment of an exacerbation.Methods27 patients with CF were recruited at onset of pulmonary exacerbation. Sputum and serum were collected at the start and end of anti-biotic therapy. Sputum calprotectin, interleukin-8 (IL8), and myeloperoxidase (MPO) were measured, as were serum calprotectin, CRP and vascular endothelial growth factor (VEGF).ResultsSputum calprotectin decreased following treatment of an exacerbation (p<0.05), and wa...